Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss discussion focused on 2% Fluridil's peak efficacy at 3 months and 7% Fluridil group buy results, including shedding decrease, side effects, and regrowth.

A user is experiencing androgenic alopecia and is considering using Vichy's aminexil for hair regrowth. They seek advice on its effectiveness and whether to combine it with microneedling.

The user is seeking help with using Ell-Cranell for hair loss treatment. They are unsure about the correct application method and dosage. They also inquire about combining microneedling with topical alfatradiol and question a study that referred to alfatradiol as a hair growth inhibitor in male mice.

The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.

Taurine shows potential in combating hair loss caused by chemical stress, especially when combined with other treatments like finasteride. Finasteride demonstrated better stress-reducing effects in the study.

Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.

User has used Finasteride, Minoxidil, and derma roller for 8 years to treat hair loss but is still losing the battle. Others suggest trying Dutasteride, oral Minoxidil, RU58841, or considering a hair transplant.

A user is seeking a new source for RU58841 in the EU after their previous supplier stopped selling it. They mention considering Anagen, Actifolic, Minoxidilmax, and rudirect, and are using a treatment mixing RU58841 with Stemoxydine and Alfatradiol.

A user is seeking a new source for RU58841 in the EU after their previous supplier stopped selling it. They mention considering Anagen, Actifolic, Minoxidilmax, and rudirect, and are using a treatment mixing RU58841 with Stemoxydine and Alfatradiol.

PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.

Keratin fusion bonds are discussed as an alternative to clip-on hair patches for men with diffused thinning. The conversation explores different styling options for hair loss.

The user has maintained hair with topical minoxidil (8%) and finasteride (0.01%) for 7.5 years, experiencing mild regrowth and no side effects. They also use rosemary oil, jojoba oil, and magnesium oil for hair care.

A user's progress pictures showing the results of taking Fin (0.5 mg per day), Min (5 mg per day) and microneedling with Dr. Pen Ultima M8; another user asked when the regrowth was noticed, and commented on the hair appearing darker.

Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.

Fluridil, also known as Topilutamide or Eucapil, is discussed as a treatment for hair loss. It is noted as an androgen receptor antagonist, not a vasodilator.

A healthy scalp barrier is crucial for hair growth, and ceramides may play a key role in maintaining it. The conversation suggests that focusing on scalp health, alongside treatments like Minoxidil, Finasteride, and RU58841, could improve hair follicle health.

The conversation is about analyzing receded temple closeups for signs of fibrosis, scarring, or androgenetic alopecia (AGA). Specific treatments like Minoxidil, finasteride, or RU58841 are not mentioned in the conversation.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

The conversation discusses a new product from Actifolic, which combines RU58841 and GHK-CU for hair loss treatment. The participants are considering whether it's worth trying.

The conversation is about using Xeljanz for hair regrowth in individuals with LPP. The user is seeking experiences and expectations from others who have tried this treatment.

User found hair loss stabilization without side effects using a topical solution of 0.008% Finasteride, 2% RU, and Stemoxydine. Other treatments like Eucapil, Fluridil, RU-monotherapy, and Pyrilutamide didn't work for them.

A user is considering mixing Stemoxydine, RU-58841, Alfatradiol, and Tretinoin into a single topical solution for hair loss. They are concerned about potential interactions that could reduce the effectiveness of these ingredients.

The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.

Copper peptides for hair loss, discussing carriers for skin penetration and recommending a product from Amazon.

RU58841 combined with finasteride or dutasteride is more effective than RU58841 alone for hair loss. Users suggest combining these with minoxidil and microneedling for better results.

A user who reported positive results from using 1.0mg Finasteride daily and 1.5mm Microneedling every two weeks for eight months, as well as advice about adding Minoxidil to further improve the regrowth process.

Hair loss treatment should target dermal white adipose tissue (DWAT) to restore hair follicles. Potential remedies include tocopherol (vitamin E), botox, rosiglitazone, niacin, kojyl cinnamate esters, and ADP355.

The user experienced side effects from RU58841, including dry eyes and potential eyesight issues, and decided to stop using it. They confirmed the product's legitimacy but advised caution due to its experimental status and lack of safety data.

The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

A user shared their 3-month progress using RU58841, 10% minoxidil, and microneedling every two weeks for hair loss. They found the new minoxidil sprayer effective for applying the treatment across the scalp.